Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes and obesity, yet their actions extend beyond glycemic control and weight loss. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.